Price of lung cancer targeted drug Mobotinib (Moboxetinib)

Mobotinib, also known as mobotinib, is an innovative oral tyrosine kinase inhibitor (TKI). This drug is groundbreaking because it is the first drug designed to selectively target epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Now, this drug has been launched in the domestic market, bringing new treatment hope to patients. However, unfortunately, despite its remarkable efficacy, mobotinib has not yet been included in my country's medical security system. This means that patients who need this drug must bear the entire cost themselves, which undoubtedly brings a considerable financial burden to patients and their families.

At present, the price of Mobotinib imported from the United States has soared to 40,000 to 50,000 yuan, which is undoubtedly a heavy financial pressure for most ordinary families. High drug prices may be prohibitive for some patients, so it is particularly important to find more ways and options to purchase drugs.

In addition to purchasing in the domestic market, patients can also consider looking for more economical sources of drugs from overseas markets. For example, the clinical version of Mobotinib sold by Japan's Takeda Pharmaceutical in Hong Kong has a clear price advantage over the domestic version, costing only 7,000, providing patients with more choices.

In addition, there are also generic versions of Mobotinib sold through regular channels in Laos and Bangladesh. These generic drugs are highly similar in ingredients to the original drugs, but are more affordable. Specifically, the latest price of the Laos version of 40mg120 tablets of Mobotinib is about 4000 yuan; while the price of the Bangladeshi version of 40mg60 capsules is around 3600 yuan. These relatively low-priced generic drugs provide patients with more economical treatment options.